Draft:Laprophan
 | Review waiting, please be patient.
This may take 2 months or more, since drafts are reviewed in no specific order. There are 2,812 pending submissions waiting for review.
Where to get help
How to improve a draft
You can also browse Wikipedia:Featured articles and Wikipedia:Good articles to find examples of Wikipedia's best writing on topics similar to your proposed article. Improving your odds of a speedy review To improve your odds of a faster review, tag your draft with relevant WikiProject tags using the button below. This will let reviewers know a new draft has been submitted in their area of interest. For instance, if you wrote about a female astronomer, you would want to add the Biography, Astronomy, and Women scientists tags. Editor resources
Reviewer tools
|
Comment: In accordance with the Wikimedia Foundation's Terms of Use, I disclose that I have been paid by my employer for my contributions to this article. LPH2026 (talk) 12:29, 11 November 2025 (UTC)
| Laprophan | |
Native name | Laboratoires de Produits Pharmaceutiques d'Afrique du Nord |
| Company type | Société anonyme |
| Industry | Pharmaceuticals |
| Founded | 1949 |
| Founder | Abderrahim Bennis |
| Headquarters | Casablanca , Morocco |
Key people | Dr Farid Bennis (chairman & CEO); Reda Bennis (vice-president) |
| Website | laprophan |
Laprophan is a Moroccan pharmaceutical company founded in 1949 in Casablanca by Abderrahim Bennis.[1] The company manufactures and distributes medicines in Morocco and exports to markets in Africa and the Middle East.[2] Dr Farid Bennis has served as chairman and CEO since June 2020; he previously held the CEO position until 2011.[3][4]
History
[edit]Laprophan traces its origins to 1949 in Casablanca.[5] On 3 May 2011, CEO Farid Bennis resigned from his functions.[6] He returned as chairman and CEO following a board decision in June 2020.[7][8]
Ownership and financing
[edit]In 2023 a consortium led by Mediterrania Capital Partners (fund MC IV), alongside development finance institutions DEG, Proparco and FMO, made a minority investment in Laprophan, reported at about €75 million.[9][10][11][12]
Operations
[edit]Laprophan operates as a Moroccan société anonyme active in manufacturing, distribution, import and export of medicines, with export activity to more than 30 countries in Africa and the Middle East.[13]
Products
[edit]Laprophan markets prescription and over-the-counter medicines in several therapeutic areas. Selected brands include:
- DI-INDO (indomethacin).[14]
- IXOR (omeprazole).[15]
- LEVAMOX (amoxicillin/clavulanic acid).[16]
- NEOFORTAN (phloroglucinol).[17]
Acquisitions and expansion
[edit]- Amanys Pharma – announced acquisition (10 November 2023), subject to regulatory approvals.[18][19]
- AIF Pharma Maroc – Competition Council approved Laprophan's 100% acquisition (26 February 2024).[20][21]
- Botanic Pharma – notification of planned acquisition of control (1 July 2024).[22]
- Europhan – Laprophan announced a European platform branded Europhan (May 2024).[23]
- Planned European acquisitions – notification of a joint acquisition (with investor Piero Luigi Umberto Poli) of 60% of Pian Holding BV, 60% of Double-e Pharma Limited and 60% of Rivopharm Limited (23 October 2025).[24]
Partnerships and recent developments
[edit]In 2023 Laprophan and Sinopharm signed a strategic cooperation agreement (10 February) and a memorandum of understanding focused on African markets (1 November).[25][26] In November 2025, Novo Nordisk and Laprophan announced the launch of semaglutide in Morocco.[27][28]
Legal matters
[edit]In March 2024 the Casablanca Commercial Court issued a first-instance ruling concerning the Fluocaril trademark, reported by business media.[29]
See also
[edit]References
[edit]- ^ "Project detail – Laprophan". FMO – Dutch entrepreneurial development bank. 4 May 2023. Retrieved 11 November 2025.
- ^ "Project detail – Laprophan". FMO. 4 May 2023. Retrieved 11 November 2025.
- ^ "Un nouveau PDG pour Laprophan". L'Économiste (in French). 22 June 2020. Retrieved 11 November 2025.
- ^ "Alerte : le PDG de Laprophan démissionne". Infomediaire (in French). 3 May 2011. Retrieved 11 November 2025.
- ^ "Project detail – Laprophan". FMO. 4 May 2023. Retrieved 11 November 2025.
- ^ "Alerte : le PDG de Laprophan démissionne". Infomediaire (in French). 3 May 2011. Retrieved 11 November 2025.
- ^ "Nomination d'un nouveau P-DG à la tête de la Laprophan". Médias24 (in French). 22 June 2020. Retrieved 11 November 2025.
- ^ "Farid Bennis nommé PDG de Laprophan". Le Matin (in French). 22 June 2020. Retrieved 11 November 2025.
- ^ "Mediterrania Capital Partners, DEG, Proparco and FMO invest €75 million in Laprophan". Mediterrania Capital Partners. 11 May 2023. Retrieved 11 November 2025.
- ^ "Mediterrania Capital Partners, DEG, Proparco et FMO investissent 75 millions d'euros dans Laprophan". Proparco (in French). 11 May 2023. Retrieved 11 November 2025.
- ^ "DEG invests in Moroccan pharmaceutical company Laprophan". DEG. May 2023. Retrieved 11 November 2025.
- ^ "Project detail – Laprophan". FMO. 4 May 2023. Retrieved 11 November 2025.
- ^ "Project detail – Laprophan". FMO. 4 May 2023. Retrieved 11 November 2025.
- ^ "DI-INDO 50 mg, comprimé effervescent". Medicament.ma (in French). Retrieved 11 November 2025.
- ^ "IXOR 20 mg, comprimé effervescent". Medicament.ma (in French). Retrieved 11 November 2025.
- ^ "LEVAMOX 1 g/125 mg, comprimé effervescent". Medicament.ma (in French). Retrieved 11 November 2025.
- ^ "NEOFORTAN 160 mg, comprimé effervescent". Medicament.ma (in French). Retrieved 11 November 2025.
- ^ "Laprophan annonce l'acquisition d'Amanys Pharma de SPE Capital et Proparco". TelQuel (in French). 10 November 2023. Retrieved 11 November 2025.
- ^ "DLA Piper advises SPE Capital on the sale of Amanys Pharma to Laprophan". DLA Piper. 14 November 2023. Retrieved 11 November 2025.
- ^ "Communiqué relatif à la réunion du 26 février 2024". Conseil de la concurrence (in French). 26 February 2024. Retrieved 11 November 2025.
- ^ "Le Conseil de la concurrence approuve le rachat de AIF Pharma Maroc par Laprophan". Médias24 (in French). 28 February 2024. Retrieved 11 November 2025.
- ^ "Communiqué – Projet de concentration Laprophan/Botanic Pharma" (PDF). Conseil de la concurrence (in French). 1 July 2024. Retrieved 11 November 2025.
- ^ "Laprophan se lance sur le marché pharmaceutique européen avec Europhan". Médias24/LeBoursier (in French). 14 May 2024. Retrieved 11 November 2025.
- ^ "Communiqué – Projet de concentration Laprophan/Pian Holding BV/Double-e Pharma Ltd/Rivopharm Ltd" (PDF). Conseil de la concurrence (in French). 23 October 2025. Retrieved 11 November 2025.
- ^ "Accord stratégique entre Laprophan et Sinopharm". Médias24 (in French). 10 February 2023. Retrieved 11 November 2025.
- ^ "Laprophan et Sinopharm s'allient pour conquérir le marché africain". Médias24 (in French). 1 November 2023. Retrieved 11 November 2025.
- ^ "Maroc : Novo Nordisk et Laprophan lancent Sémaglutide". L'Économiste (in French). 6 November 2025. Retrieved 11 November 2025.
- ^ "L'Ozempic officiellement lancé au Maroc, sur fond de controverse". Médias24 (in French). 5 November 2025. Retrieved 11 November 2025.
- ^ "Bataille Laprophan/Unilever autour du dentifrice Fluocaril". Médias24 (in French). 14 March 2024. Retrieved 11 November 2025.